Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema The Pan-American Collaborative Retina Study Group Results

Objective: To determine the feasibility, safety, and clinical effect of intravitreal (IVT) bevacizumab (Avastin; Genentech, Inc., San Francisco, CA) in patients with refractory cystoid macular edema (CME) after cataract surgery. Design: Interventional, retrospective, multicenter study.

• Fecha de publicación: 2009
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/26147
• Acceso en línea: https://doi.org/10.1016/j.ophtha.2009.04.006; https://repository.urosario.edu.co/handle/10336/26147
• Palabra clave: Aged; Aged; 80 and over; Angiogenesis Inhibitors; Antibodies; Monoclonal; Antibodies; Monoclonal; Humanized; Bevacizumab; Cataract Extraction; Feasibility Studies; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Injections; Macular Edema; Male; Postoperative Complications; Pseudophakia; Retrospective Studies; Tomography; Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body
• License: Restringido (Acceso a grupos específicos)